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1. INTRODUCTION {#jcla23304-sec-0005}
===============

The breast cancer (BC) has been reported to be a primary cause of malignancy and mortality in women, and the incidence rate worldwide has been on the rise.[^1^](#jcla23304-bib-0001){ref-type="ref"} The breast cancer possesses a heterogeneous nature and is classified into several subtypes.[^2^](#jcla23304-bib-0002){ref-type="ref"} Anti‐estrogen or combined anti‐HER2 therapeutic strategies are major treatments for luminal A, luminal B, and HER2‐positive (HER2+) breast cancer subtypes.[^3^](#jcla23304-bib-0003){ref-type="ref"} However, the highly aggressive and metastatic triple‐negative breast cancer (TNBC, negative in estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) is associated with high relapse even after chemotherapy or radiotherapy.[^4^](#jcla23304-bib-0004){ref-type="ref"}, [^5^](#jcla23304-bib-0005){ref-type="ref"} Therefore, unraveling novel and effective targets for TNBC intervention are of great significance.

Growing evidence has suggested that the non‐coding RNAs with no or minimal coding abilities contribute largely to tumor development.[^6^](#jcla23304-bib-0006){ref-type="ref"} A major constituent of non‐coding transcriptome is long non‐coding RNAs (lncRNAs).[^6^](#jcla23304-bib-0006){ref-type="ref"} The long non‐coding RNAs are RNA transcripts with more than 200 nucleotides in length and involved in numerous biological processes.[^7^](#jcla23304-bib-0007){ref-type="ref"} The lncRNAs can serve as an oncogene or tumor suppressor with an emerging effect on metastasis.[^8^](#jcla23304-bib-0008){ref-type="ref"} For instance, Tang et al identified that lncRNA PVT1 can stabilize KLF5 via BAP1 and increase its stability to promote TNBC progression.[^9^](#jcla23304-bib-0009){ref-type="ref"} Alipoor et al recently found that lncRNA MIAT increases miR‐302/miR‐150 expression, whereas miR‐29c expression was decreased.[^10^](#jcla23304-bib-0010){ref-type="ref"} Furthermore, MIAT also abolishes the expression of p16^Ink4A^ and Cox2 to inhibit senescence commitment.[^10^](#jcla23304-bib-0010){ref-type="ref"} A TNBC‐specific lncRNA LINC00511 is markedly upregulated through gene amplification and significantly correlates with TNBC progression.[^11^](#jcla23304-bib-0011){ref-type="ref"} Sas‐Chen et al showed that lncRNA LIMT is a highly conserved tumor suppressor and its expression is suppressed by epidermal growth factor (EGF) signaling pathway.[^12^](#jcla23304-bib-0012){ref-type="ref"} Other reported lncRNAs (eg, RMST and BORG) are substantially associated with breast cancer development via diverse molecular mechanisms.[^13^](#jcla23304-bib-0013){ref-type="ref"}, [^14^](#jcla23304-bib-0014){ref-type="ref"} However, the function of lncRNAs especially in TNBC is still obscure.

In the current work, by lncRNA profiling, we have identified a novel lncRNA ENSG00000259457 as an oncogenic lncRNA in TNBC. It was termed as [o]{.ul}ncogenic [l]{.ul}ncRNA in [b]{.ul}reast [c]{.ul}ancer on chromosome 15 (OLBC15). We observed that OLBC15 is significantly upregulated in TNBC. OLBC15 acted as an oncogenic factor to promote breast cancer progression, and this effect was verified both in vivo and in vitro. Furthermore, by RNA immunoprecipitation we noted that zinc‐finger protein‐326 (ZNF326) might be an OLBC15 binding protein. The interaction of OLBC15 and ZNF326 decreased the stability of ZNF326 via enhanced ubiquitination and proteasomal degradation. OLBC15 also showed negative correlation with ZNF326 protein expression in clinical samples. These data collectively implied an oncogenic role of OLBC15 and may provide a novel anti‐TNBC target for therapeutic intervention.

2. MATERIALS AND METHODS {#jcla23304-sec-0006}
========================

2.1. Cell lines, lentiviral vectors, and reagents {#jcla23304-sec-0007}
-------------------------------------------------

The transformed MCF‐10A and breast cancer MDA‐MB‐231, BT‐549, HCC1806, Hs578t, and MDA‐MB‐468 cells were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM, Sigma) containing 7% FBS and 150 μg/mL streptomycin. The cell lines were all obtained from Cell Resource Center of Shanghai Institute of Biological Sciences (CAS). Puromycin was used for 2 days. OLBC15 was first cloned and was then inserted into a pWPXL vector (Biovector) to generate pWPXL‐OLBC15 vector (OE‐OLBC15). Lentiviral selection was then conducted using puromycin (No.A1113802, Thermo Fisher Scientific), and generated supernatants were treated with a syringe filter. An empty pWPXL vector serves as the control (ie, OE‐control). The short hairpin RNA (shRNA) for OLBC15 (ShOLBC15) together with a non‐targeting scrambled control (ShCtrl) was obtained from Biovector. Transfection was conducted using Lipofectamine 3000. Primers were listed in Table [S1](#jcla23304-sup-0001){ref-type="supplementary-material"}.

2.2. Human samples {#jcla23304-sec-0008}
------------------

The breast cancer tissues were collected from patients following a protocol described previously[^15^](#jcla23304-bib-0015){ref-type="ref"} from January 2017 to November 2018. The samples were stored at −80℃ immediately after resection before use. Experiments associated with human specimens were approved by Human Research Ethics Committee (HREC) at Chongqing Three Gorges Central Hospital in accordance with the 1975 Declaration of Helsinki.

2.3. Migration assay {#jcla23304-sec-0009}
--------------------

\~5 × 10^5^ cells were located on the top chamber of a 24‐well plate (BD Biosciences). The DMEM with 7% serum was loaded at the bottom. After an incubation for 24 hours, cells moving into the bottom chambers were fixed with 4% paraformaldehyde (No.16005, Sigma) and subject to staining by 0.4% crystal violet (No.C0775, Sigma).

2.4. Viability assay {#jcla23304-sec-0010}
--------------------

We used Cell Counting Kit‐8 (CCK‐8, Dojindo, Japan) to measure the viability of breast cancer cells following the manufacturer\'s protocols. BT549 and MDA‐MB‐231 cells were resuspended and moved into a 12‐well plate (\~2 × 10^5^ cells/well). 30 µL CCK‐8 solutions were then added into the system. Optical density at 450 nm (OD 450 nm) was measured by a Spectramax M5 microplate monitor (Molecular Devices).

2.5. Statistical analysis {#jcla23304-sec-0011}
-------------------------

Statistical analyses were performed with SPSS (v16, SPSS, Inc). Data were represented as mean ± SD. The nonparametric Mann‐Whitney test was used to identify the statistical significance between two groups, and ANOVA was used for comparing multiple groups followed by the LSD post hoc test. *P* \< .05 was considered statistically significant.

3. RESULTS {#jcla23304-sec-0012}
==========

3.1. Identifying OLBC15 in breast cancer via lncRNA profiling {#jcla23304-sec-0013}
-------------------------------------------------------------

To screen for breast cancer (BC)‐related lncRNAs, we used lncRNA profiling assays in paired BC tissues and normal adjacent tissues (NATs) (Figure [1A](#jcla23304-fig-0001){ref-type="fig"}). Overall, 73 significantly upregulated lncRNAs were detected (Figure [1A](#jcla23304-fig-0001){ref-type="fig"}). These lncRNAs were candidate ones with oncogenic potential. Notably, two novel lncRNAs, RP11‐597D13.9 and OLBC15, were identified by lncRNA profiling (Table [S2](#jcla23304-sup-0001){ref-type="supplementary-material"}). Since lncRNA OLBC15 showed higher fold expression, we chose it for further analysis. OLBC15 was markedly upregulated in BC tissues compared with normal tissues (Figure [1B](#jcla23304-fig-0001){ref-type="fig"}). OLBC15 is located on chromosome 15 with one annotated transcript ([www.ensembl.org](http://www.ensembl.org)). The whole sequence for OLBC15 was shown (Figure [S1](#jcla23304-sup-0001){ref-type="supplementary-material"}A). Full‐length OLBC15 showed neglectable coding potential as evaluated by Coding Potential Assessment Tool (CPAT, coding probability \~ .032, Figure [S1](#jcla23304-sup-0001){ref-type="supplementary-material"}B). Moreover, OLBC15 was substantially enriched in triple‐negative breast cancer (TNBC) tissues compared with the other subtypes (Figure [1C](#jcla23304-fig-0001){ref-type="fig"}). OLBC15 transcripts were highly increased in BC cell lines compared with MCF10A cells (Figure [1D](#jcla23304-fig-0001){ref-type="fig"}). Patient characteristics demonstrated that OLBC15 expression significantly correlated with TNM stage, tumor size, and metastasis but was not significantly associated with age and histology (Table [S3](#jcla23304-sup-0001){ref-type="supplementary-material"}). Subcellular fractionation assay clarified that OLBC15 was primarily located in nucleus (Figure [1E](#jcla23304-fig-0001){ref-type="fig"}). These data suggested that OLBC15 was upregulated in BC with nuclear distribution.

![Identifying OLBC15 in breast cancer (BC). A, Heatmap representation of lncRNA profiling in normal adjacent tissues (NATs) and breast cancer tissues. Significantly upregulated and downregulated lncRNAs in BC tissues were 73 and 126, respectively. B, Relative OLBC15 expression in NAT and BC tissues. C, The relative OLBC15 levels in different breast cancer subtypes. The case numbers for luminal A (LA), luminal B (LB), HER2^+^ (HER2), and triple‐negative breast cancer (TNBC) were 40, 25, 26, and 51, respectively. D, Relative OLBC15 expression in transformed MCF10A and cancerous TNBC cell lines. E, Subcellular distribution of OLBC15. \*\*: *P* \< .01](JCLA-34-e23304-g001){#jcla23304-fig-0001}

3.2. OLBC15 facilitates breast cancer progression in vitro {#jcla23304-sec-0014}
----------------------------------------------------------

We next checked whether OLBC15 had an effect in vitro. We first stably overexpressed or silenced OLBC15 expression in MDA‐MB‐231 and BT‐549 cells (Figure [2A](#jcla23304-fig-0002){ref-type="fig"},[B](#jcla23304-fig-0002){ref-type="fig"}). The knockdown and overexpression efficiency were verified (Figure [2A](#jcla23304-fig-0002){ref-type="fig"},[B](#jcla23304-fig-0002){ref-type="fig"}). As expected, OLBC15 overexpression significantly promoted the viability of BT‐549 and MDA‐MB‐231 cells (Figure [2C](#jcla23304-fig-0002){ref-type="fig"},[D](#jcla23304-fig-0002){ref-type="fig"}). Consistently, OLBC15 depletion (shOLBC15) strongly inhibited the viability of breast cancer cells (Figure [2C](#jcla23304-fig-0002){ref-type="fig"},[D](#jcla23304-fig-0002){ref-type="fig"}). Migration assay further suggested that OLBC15 overexpression advanced migration in BT‐549 and MDA‐MB‐231 cells (Figure [2E](#jcla23304-fig-0002){ref-type="fig"},[F](#jcla23304-fig-0002){ref-type="fig"}; *P* \< .01). OLBC15 silence instead attenuated migratory capacity in breast cancer cells (Figure [2E](#jcla23304-fig-0002){ref-type="fig"},[F](#jcla23304-fig-0002){ref-type="fig"}). These results implied that OLBC15 might play an oncogenic role in vitro.

![OLBC15 promotes TNBC in vitro. A, Overexpression efficiency by lentiviral OLBC15 transfection. B, Knockdown efficiency using shRNA targeting OLBC15. ShOLBC15 displayed higher efficiency and was selected as ShOLBC15. C‐D, Effect of OLBC15 on viability of BT‐549 (C) and MDA‐MB‐231 (D) cells transfected with shRNA scrambled control (ShCtrl), ShOLBC15, lentiviral control (OE‐control), or the lentiviral vector carrying OLBC15 (OE‐OLBC15). E, Effect of OLBC15 on migratory capacity of MDA‐MB‐231 (top) and BT‐549 (bottom) cells. F, Quantification of results in (E). \*\*: *P* \< .01](JCLA-34-e23304-g002){#jcla23304-fig-0002}

3.3. OLBC15 promotes xenograft tumor growth and metastasis {#jcla23304-sec-0015}
----------------------------------------------------------

We then performed in vivo experiments to further investigate the function of OLBC15. Stably transfected MDA‐MB‐231 cells were used. OLBC15 knockdown inhibited tumor growth, whereas overexpressing OLBC15 promoted the tumor volume expansion (Figure [3A](#jcla23304-fig-0003){ref-type="fig"}). A higher number of metastatic nodules were detected in OLBC15‐overexpressing group compared with the control (Figure [3B](#jcla23304-fig-0003){ref-type="fig"},[C](#jcla23304-fig-0003){ref-type="fig"}; *P* \< .01). As expected, OLBC15 silence profoundly inhibited the occurrence of metastatic nodules (Figure [3B](#jcla23304-fig-0003){ref-type="fig"},[C](#jcla23304-fig-0003){ref-type="fig"}; *P* \< .01). The xenograft tumor growth was evidently attenuated by OLBC15 depletion, whereas OLBC15 overexpression markedly accelerated the growth of xenograft tumors (Figure [3E](#jcla23304-fig-0003){ref-type="fig"},[F](#jcla23304-fig-0003){ref-type="fig"}; *P* \< .01). These results further suggested that OLBC15 could exert an oncogenic effect in vivo.

![OLBC15 advances TNBC in vivo. A, In vivo tumor volume growth of xenograft tumors with OLBC15 depletion or overexpression. B, Representative lung metastatic nodules with OLBC15 silence or overexpression. The description representing each numbered case was shown at the bottom. C, Quantification of metastatic nodules in (B). D, Xenograft tumors for MDA‐MB‐231 transplantation model with OLBC15 silence or overexpression. Numbered case description was shown at the bottom. E, Quantification data for (D). \*\*: *P* \< .01](JCLA-34-e23304-g003){#jcla23304-fig-0003}

3.4. OLBC15 interacts with ZNF326 protein {#jcla23304-sec-0016}
-----------------------------------------

We further used RNA pulldown assays to unravel the potential mechanism of OLBC15‐induced oncogenic effect. One specific band was detected (Figure [4A](#jcla23304-fig-0004){ref-type="fig"}; indicated by arrow). The enriched proteins in OLBC15 pulldowns were then analyzed using mass spectrometry, and the results showed five putative hits (Table [S4](#jcla23304-sup-0001){ref-type="supplementary-material"}). Immunoblot confirmed that ZNF326 may be binding factor (Figure [4B](#jcla23304-fig-0004){ref-type="fig"}). OLBC15 was significantly enriched in fractions with antibody against ZNF326 as determined by measuring co‐precipitated RNA (Figure [4C](#jcla23304-fig-0004){ref-type="fig"}). Fluorescence in situ hybridization (FISH) also revealed colocalization for OLBC15 and ZNF326 (Figure [4D](#jcla23304-fig-0004){ref-type="fig"}). Full‐length and various ZNF326 truncated mutants were constructed (Figure [4E](#jcla23304-fig-0004){ref-type="fig"}), and we found that depleting the C‐terminal region of ZNF326 markedly abolished its interaction with OLBC15 (Figure [4F](#jcla23304-fig-0004){ref-type="fig"}). Various OLBC15 truncated forms were also created according to the predicted secondary structure (Figure [4G](#jcla23304-fig-0004){ref-type="fig"},H). The results showed that the N‐terminal domain of OLBC15 was responsible for ZNF326 binding (Figure [4I](#jcla23304-fig-0004){ref-type="fig"}). These results showed that OLBC15 may interact with ZNF326 protein.

![ZNF326 interacts with OLBC15. A, RNA pulldown for lncRNA OLBC15. The indicates band was trimmed and subject to mass spectrometry (MS) analyses. B, Proteins obtained from RNA pulldowns were analyzed by antibody for ZNF326. C, RNA immunoprecipitation (RIP) results for OLBC15. The lncRNA LINC00501 was used as a negative control. D, Fluorescence in situ hybridization (FISH) to show the colocalization of OLBC15 and ZNF326. E, Full‐length and depletion constructs of ZNF326 were used to locate the binding region for OLBC15. F, RNA immunoprecipitation (RIP) followed by qRT‐PCR in DMA‐MB‐231 cells transfected with ectopic expression for full‐length (FL) Flag‐tagged ZNF326 or various mutant constructs. G, The secondary structure of OLBC15 predicted by an online tool termed RNAfold ([http://rna.tbi.univie.ac.at//cgi‐bin/RNAWebSuite/RNAfold.cgi](http://rna.tbi.univie.ac.at//cgi-bin/RNAWebSuite/RNAfold.cgi)). The black box depicts the binding region for ZNF326. H, Construction of full‐length (FL) or various OLBC15 truncates. I, RIP followed by qRT‐PCR to show the putative interacting domain for OLBC15 with ZNF326. Fold enrichment data were rescaled by comparing each input with Flag‐Vec](JCLA-34-e23304-g004){#jcla23304-fig-0004}

3.5. OLBC15 facilitates ZNF326 degradation {#jcla23304-sec-0017}
------------------------------------------

To confirm the underlying mechanism of OLBC15‐ZNF326 binding, we knocked down OLBC15 expression in MDA‐MB‐231 cells and we found that ZNF326 abundance was increased (Figure [5A](#jcla23304-fig-0005){ref-type="fig"}). Co‐treatment with MG132, a proteasomal inhibitor, however, could elevate ZNF326 levels irrespective of whether OLBC15 was silenced (Figure [5B](#jcla23304-fig-0005){ref-type="fig"}). OLBC15 knockdown substantially inhibited ZNF326 ubiquitination (Figure [5C](#jcla23304-fig-0005){ref-type="fig"}). However, OLBC15 overexpression or depletion did not affect *ZNF326* mRNA levels (Figure [5D](#jcla23304-fig-0005){ref-type="fig"}). Migration assays revealed that knocking down OLBC15 could significantly inhibit breast cancer cell migration (Figure [5E](#jcla23304-fig-0005){ref-type="fig"},[F](#jcla23304-fig-0005){ref-type="fig"}). However, this effect could be counteracted by combinatorial ZNF326 silence (Figure [5E](#jcla23304-fig-0005){ref-type="fig"},[F](#jcla23304-fig-0005){ref-type="fig"}). The efficiency of ZNF326 silence was also verified (Figure [5G](#jcla23304-fig-0005){ref-type="fig"}). Previous study has shown that ZNF326 can bind the promoter region of Krüppel‐like factor 17 (*KLF17*) gene and induce KLF17 expression.[^16^](#jcla23304-bib-0016){ref-type="ref"} OLBC15 knockdown indeed dramatically upregulated *KLF17* expression, whereas *KLF17* expression was inhibited after ZNF326 was silenced (Figure [S2](#jcla23304-sup-0001){ref-type="supplementary-material"}A). Notably, *KLF17* level was partially rescued with simultaneous ZNF326/OLBC15 silence (Figure [S2](#jcla23304-sup-0001){ref-type="supplementary-material"}A). The occupancies of ZNF326 to *KLF17* promoter were also increased when OLBC15 was depleted (Figure [S2](#jcla23304-sup-0001){ref-type="supplementary-material"}B). These data suggested that OLBC15 could promote ZNF326 degradation via ubiquitination pathway.

![OLBC15 destabilizes ZNF326 by increasing ubiquitination. A, ZNF326 expression in MDA‐MB‐231 cells transfected with ShCtrl or two shOLBC15 constructs. B, ZNF326 expression in MDA‐MB‐231 cells with or without OLBC15 silence treated with DMSO (MG132‐) or MG132 (MG132+). C, Ubiquitin ligation of ZNF326 in MDA‐MB‐231 cells with or without OLBC15 depletion expressing full‐length Flag‐tagged ZNF326. D, Relative expression of *ZNF326* transcripts with either OLBC15 knockdown or overexpression. E, Migration assays for MDA‐MB‐231 cells with OLBC15 knockdown and/or *ZNF326* shRNA. F, Quantification data for cellular migration in (E). G, Efficiency of ZNF326 silence on ZNF326 expression. ShZNF326‐2 showed higher efficiency and was selected as ShZNF326. \*\*: *P* \< .01](JCLA-34-e23304-g005){#jcla23304-fig-0005}

3.6. Correlation between OLBC15 and ZNF326 in clinical samples {#jcla23304-sec-0018}
--------------------------------------------------------------

We further investigated the clinical relevance of OLBC15 and ZNF326 in human samples. Immunohistochemistry (IHC) analyses showed various degrees of ZNF326 expression with different intensity scores which represented ZNF326 expression status (Figure [6A](#jcla23304-fig-0006){ref-type="fig"}). Consistently, we found that OLBC15 level was not significantly associated with *ZNF326* transcripts (Figure [6B](#jcla23304-fig-0006){ref-type="fig"}). However, a significantly negative correlation was evident between ZNF326 protein expression and OLBC15 (Figure [6C](#jcla23304-fig-0006){ref-type="fig"}). These results suggested that OLBC15 could inhibit ZNF326 expression in clinical specimens.

![Correlation between OLBC15 and ZNF326 in clinical samples. A, Immunohistochemical (IHC) staining to identify ZNF326 in human specimens. Representative low (0), weak (1+), intermediate (2+), and strong staining (3+) cases using H‐score method were shown. Scale bar: 100 μm. B, Pearson correlation coefficient (*R*) between OLBC15 and *ZNF326* mRNA abundance. The *P* value was shown. C, Correlation between OLBC15 levels and ZNF326 IHC scores (ie, protein abundance) in clinical samples](JCLA-34-e23304-g006){#jcla23304-fig-0006}

4. DISCUSSION {#jcla23304-sec-0019}
=============

In the current study, we have identified a novel oncogenic lncRNA OLBC15. We found that OLBC15 depletion may exert profound inhibition to breast cancer progression implying that OLBC15 may act as a putative target for intervention. OLBC15 expression was dramatically increased in breast cancer tissues especially TNBC. Furthermore, we also observed an oncogenic effect of OLBC15 via both in vitro and in vivo experiments. Mechanistic study showed that OLBC15 could interact with ZNF326, which is a novel tumor suppressor in TNBC.[^16^](#jcla23304-bib-0016){ref-type="ref"} OLBC15 facilitates ZNF326 degradation via ubiquitination pathway. These data collectively suggested that OLBC15 fulfills its oncogenic function via destabilizing the tumor suppressor ZNF326. Notably, the ubiquitin ligase responsible for ZNF326 is still elusive and whether OLBC15 enhances the interaction between ZNF326 and its ubiquitin ligase remains to be determined. Moreover, the possibility of OLBC15 as a competitive endogenous RNA (ceRNA) during breast cancer progression remains to be evaluated.[^17^](#jcla23304-bib-0017){ref-type="ref"}

We found that OLBC15 interacts with ZNF326 to destabilize ZNF326 protein. The ZNF326 protein is initially identified in NIH3T3 cell line and modulates migration and growth.[^18^](#jcla23304-bib-0018){ref-type="ref"} Meanwhile, ZNF326 is also a transcriptional factor which activates neuronal differentiation.[^19^](#jcla23304-bib-0019){ref-type="ref"} ZNF326 can bind deleted in breast cancer 1 (DBC1) leading to the formation of DBIRD (DBC1/ZIRD) complex and result in its association with RNAPII.[^20^](#jcla23304-bib-0020){ref-type="ref"} Therefore, ZNF326 can actively participate in the process of alternative splicing in A/T‐rich regions of DNA.[^16^](#jcla23304-bib-0016){ref-type="ref"} Depleting ZNF326 can increase the expression of multiple genes involved in epithelial‐mesenchymal transition (EMT) in HEK293 cells and TNBC cell lines.[^16^](#jcla23304-bib-0016){ref-type="ref"}, [^20^](#jcla23304-bib-0020){ref-type="ref"} ZNF326 silence also leads to enhanced migratory and invasive capacity together with increased mammosphere formation in TNBC cells.[^16^](#jcla23304-bib-0016){ref-type="ref"} Consistently, ZNF326 knockdown also promotes orthologous transplant tumor formation, whereas overexpressing ZNF326 decreased xenograft tumor formation.[^16^](#jcla23304-bib-0016){ref-type="ref"} We have verified that OLBC15 silence can stabilize ZNF326 and as a result markedly augment the expression of *KLF17*, which is a well‐characterized tumor suppressor gene and negatively regulates EMT and metastasis in breast cancer.[^21^](#jcla23304-bib-0021){ref-type="ref"} Furthermore, increased expression of PRMT5/WDR77 complex in breast cancer cells results in ZNF326 methylation and is essential for Pol II elongation across A/T‐rich regions.[^22^](#jcla23304-bib-0022){ref-type="ref"} ZNF326 also represses breast cancer progression via diverse mechanisms.[^16^](#jcla23304-bib-0016){ref-type="ref"} These data support a tumor‐suppressive role of ZNF326 in TNBC. We should note that ZNF326 might play different roles in other types of cancer. For example, recent reports have demonstrated that cells with ZNF326 overexpression favor malignant phenotypes in glioma via increasing LDAC7 levels and activating Wnt signaling.[^18^](#jcla23304-bib-0018){ref-type="ref"} Wu et al have also identified that the C2H2 structure of ZNF326 can bind to the ERCC1 promoter and elevate ERCC1 expression in non--small‐cell lung cancer (NSCLC).[^23^](#jcla23304-bib-0023){ref-type="ref"} Therefore, ZNF326 can be a tumor suppressor and lncRNA OLBC15 promotes TNBC oncogenesis via destabilizing ZNF326 at least in TNBC. These data argue that OLBC15 may possibly be a tumor‐specific lncRNA in TNBC and the exact role of OLBC15 in other types of cancers remains to be investigated in future studies.

Notably, patients with TNBC suffer greatly from poor outcomes and effective target therapy is still lacking in TNBC.[^5^](#jcla23304-bib-0005){ref-type="ref"}, [^24^](#jcla23304-bib-0024){ref-type="ref"} The programmed cell death protein 1 (PD‐1)/PD ligand 1 (PD‐L1) as well as androgen receptors (AR) might be possible targets for therapeutic intervention to repress breast cancer progression although the efficiency and the frequent off‐target effects have posed serious concerns.[^5^](#jcla23304-bib-0005){ref-type="ref"} Current data have supported OLBC15 as a potential oncogenic lncRNA especially in TNBC. Therefore, the efficacy of OLBC15 targeting deserves further investigation. RNA interference might be a possible strategy; however, the lowered stability and cellular uptake especially in nucleus remain an obstacle to OLBC15 depletion.[^25^](#jcla23304-bib-0025){ref-type="ref"} The antisense oligonucleotides (ASOs) may provide a promising way to annihilate OLBC15 in breast cancer cells, and ASOs specifically targeting EZH2 and AR are highly effective in recent work.[^26^](#jcla23304-bib-0026){ref-type="ref"} A clinical trial has demonstrated that an ASO termed IONIS‐APO(a)~Rx~ can be of favorable efficiency.[^27^](#jcla23304-bib-0027){ref-type="ref"} Therefore, we argue that using ASOs targeting OLBC15 may present an alternative strategy to abolish OLBC15 expression and inhibit TNBC development. There is also a possibility to target multiple TNBC‐associated oncogenic lncRNAs via ASOs, and relevant investigations should be performed in future.

Our current data have supported a novel transcript related to TNBC progression. OLBC15 directly interacts with ZNF326 tumor suppressor and interferes its post‐translational modification. OLBC15 has potentially clinical relevance and may aid in targeted design of anti‐cancer therapeutics especially in TNBC.
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